RxDoctor Payments Data

Holly Kinnell Rust

Family · Putnam, CTNPI 1932287893

Payments from drug & device makers

$4,913in general payments, 2019–2025

Across 266 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$690
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$348
  • Gilead$342
  • Phathom Pharmaceuticals, Inc.$333
  • Ferring Pharmaceuticals Inc.$253
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,87299%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,913 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$33,625
Medicare patients
254
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$330,874
RinvoqUpadacitinib38$276,270
LinzessLinaclotide93$111,758
Cyltezo(Cf) PenAdalimumab-Adbm11$73,756
CreonLipase/Protease/Amylase25$58,854
TrulancePlecanatide31$33,250
Dexlansoprazole DrDexlansoprazole73$18,279
NexiumEsomeprazole Magnesium13$11,475
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates150$9,019
Famotidine354$8,815
Ursodiol27$8,534
ClenpiqSod Picosulf/Mag Ox/Citric Ac39$6,827
Mesalamine17$6,103
Pantoprazole Sodium403$4,859
Mercaptopurine17$3,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Creon$1,166$446,881156 claims
Johnson & JohnsonStelara$690$330,87412 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$348$33,25031 claims
Ferring Pharmaceuticals Inc.Clenpiq$253$6,82739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.

Other family in Putnam

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →